The CMTA Inherited Neuropathy Consortium Alliance (CMTA-INC) has enrolled its 10,000th patient, marking a major milestone in the search for treatments...
Your Braces Should Be Earning Their Keep: What a New Study Says About AFOs and CMT
In a new study, Dutch researchers found that AFOs can measurably improve how people with CMT walk, but it depends on how the braces are chosen and fitted.
FDA to Hold Patient Listening Session for CMT2C/TRPV4
This October, the FDA will host a Patient Listening Session for the CMT2C/TRPV4 community, organized by CMTA. During this event, the FDA will hear from people living with this form of CMT about their lives, their needs, and their hopes for new treatments.
A Backup Gene Offers a New Path to CMT2A Treatment
What if the answer to CMT2A is already in your cells? A new CMTA partnership is testing whether switching on a backup gene could protect nerves when MFN2 fails.
CMTA Invests $165,000 in CMT1A and CMT1E Treatments
CMTA invests $165,000 in University of Iowa research led by Michael Shy, MD, and Robert Piper, PhD, to determine the right time to begin treatment for CMT1A and CMT1E.
When Should Treatment Begin in CMT1A and CMT1E?
What if the timing of treatment could change everything? CMTA is funding a new study to find the optimal window for treating CMT1A and CMT1E; and to discover how to tell if it's working.
CMTA Adds $225,720 for CMT1B and CMT1E Drug Repurposing
CMTA is investing $225,720 to expand drug repurposing research into CMT1B and CMT1E, building on ongoing CMT1A research targeting shared disease mechanisms.
New Clinical Trial Recommendations Help Speed CMT Therapies
CMTA is leading efforts to improve CMT clinical trials through new recommendations that help create a clearer path for developing and approving new therapies.
Vanda Earns FDA Rare Pediatric Disease Designation for CMT2S
CMTA Strategy to Accelerate Research (CMTA-STAR) Alliance Partner Vanda Pharmaceuticals has announced that the U.S. Food...
CMTA research takes the stage at PNS
PNS 2026 showcased CMTA's role in advancing CMT research across the translational pipeline, from biomarkers and natural history studies to clinical trials, therapeutic development, and the scientific collaborations driving progress.
